Am J Transplant, Volume 16, Suppl 3 Archives - Page 170 of 180 - ATC Abstracts

2016 American Transplant Congress
Do We Need an Individually Tailored Immunosuppression Strategy for Living Donor Kidney Transplant Recipients with PreTransplant Donor Specific Antibodies? A Retrospective Analysis.
S. Bhutani,¹ A. Ponnusamy,² Q. Tak,¹ S. Shah,¹ J. Worthington,¹ A. Summers,¹ K. Poulton,¹ D. Van Dellen,¹ M. Morton,¹ M. Picton.¹
¹Department of Renal & Transplant Medicine, Manchester Royal Infirmary, Manchester, United Kingdom; ²Department of Renal Medicine, Royal Hospital Preston, Preston, United Kingdom.
Introduction:Pre-Transplant Microbead donor HLA specific antibody(DSA) positive but cell crossmatch negative transplants are considered to be at increased immunological risk. This study aimed to address…
2016 American Transplant Congress
Management and Outcomes of Upper Extremity Deep Venous Thrombosis in Heart Transplant Patients.
A. Panakos,¹ D. Kramer,¹ M. McCarey,¹ P. Mather.²
¹Internal Medicine, Thomas Jefferson University Hospital, Philadelphia, PA; ²Cardiology, Thomas Jefferson University Hospital, Philadelphia, PA.
Upper extremity deep venous thrombosis (UEDVT) is common in post-heart transplant (OHT) patients, likely due to their multiple intravascular catheters and post-surgical state. The clinical…
2016 American Transplant Congress
Four-Factor Prothrombin Complex Concentrate as a Strategy to Rapidly Reverse Anticoagulation in Patients Undergoing Cardiac Transplantation: Better Than the Conventional Approach?
T. Sam,¹ G. Gonzalez-Stawinski,² G. Saracino,³ A. Jamil,³ S. Hall,² K. Cox,¹ B. Lima.²
¹Department of Pharmacy, Baylor University Medical Center, Dallas, TX; ²Heart Transplantation and Mechanical Circulatory Support, Baylor University Medical Center, Dallas, TX; ³Baylor Research Institute, Baylor University Medical Center, Dallas, TX.
PurposeThe purpose of this analysis is to compare outcomes of administering four-factor prothrombin complex concentrate (4F-PCC, Kcentra™) versus standard of care for anticoagulation reversal in…
2016 American Transplant Congress
Basiliximab Induction for Safe Delay of Calcineurin Inhibitors in High MELD Liver Transplant Recipients.
J. Clark,¹ T. Sparkes,¹ B. Masters,¹ J. LaMattina,² R. Barth,² M. Moss.¹
¹University of Maryland Medical Center, Baltimore, MD; ²University of Maryland School of Medicine, Baltimore, MD.
Background: Available literature supports basiliximab induction for safe delay of CNI initiation and renal recovery; however there is a paucity of evidence for use in…
2016 American Transplant Congress
Quantitative Hepatitis C Virus (HCV) RNA in Plasma and Kidney Tissue in HCV Antibody Positive Donors.
H. Shike,¹ Z. Kadry,² R. Shah,² Y. Imamura,¹ W. Greene,¹ J. Gaspari,¹ T. Riely,¹ H. Nathan,³ R. Hasz,³ A. Jain.¹
¹Surgery, Transplant, Hershey Medical Center, Hershey, PA; ²Pathology, Hershey Medical Center, Hershey, PA; ³OPO, Gift of Life Donor Program, Philadelphia, PA.
Background: Currently HCV antibody positive deceased donors renal allografts are not considered for transplantation in HCV negative recipients. With recent development of anti-HCV therapy, utilization…
2016 American Transplant Congress
Replicative Senescence and Arteriosclerosis After Kidney Transplantation.
K. De Vusser,¹ D. Martens,² E. Lerut,³ D. Kuypers,¹ T. Nawrot,² M. Naesens.¹
¹Department of Nephrology and Renal Transplantation, UZ Leuven, Leuven, Belgium; ²Department of Imaging and Pathology, KULeuven, Leuven, Belgium; ³Centre for Environmental Sciences, U Hasselt, Hasselt, Belgium.
BackgroundReplicative senescence is associated with telomere shortening. In native kidneys, obtained prior to transplantation, we recently described and validated a significant association between shorter intrarenal…
2016 American Transplant Congress
Same Policy, Different Impact: Center and Regional Effects of SHARE 35 Liver Allocation.
D. Murken,¹ A. Peng,¹ D. Aufhauser Jr,¹ D. Goldberg,² M. Levine.¹
¹Surgery, University of Pennsylvania, Philadelphia, PA; ²Medicine, University of Pennsylvania, Philadelphia, PA.
Introduction: Early studies of national data suggest that Share-35 implementation was associated with more liver transplants, fewer discards, and lower waitlist mortality, without worsening of…
2016 American Transplant Congress
Factors Associated with Increased Risk of MELD Progression Among a Large Population of Patients with Cirrhosis and an Initial Low MELD Score (<15).
K. Atiemo, L. Zhao, A. Skaro, L. VanWagner, S. Goel, A. Kho, B. Ho, R. Kang, S. Montag, J. Holl, M. Abecassis, D. Ladner.
Northwestern University, Chicago.
AimsLiving donor liver transplantation (LDLT) is an underutilized resource. Timely identification of patients with cirrhosis and a low MELD who's MELD score is likely to…
2016 American Transplant Congress
Risk Factors for Short and Long Term Mortality in High MELD Recipients.
A. Bertacco,^1,2 M. Rodriguez-Davalos,¹ M. Schilsky,³ P. Yoo,¹ S. Kulkarni,¹ B. Fortune,³ A. Liapakis,³ S. Emre,¹ D. Mulligan.¹
¹Surgery, Yale University, New Haven; ²Dipartimento di Scienze Chirurgiche Oncologiche e Gastroenterologiche - DiSCOG, Padova University, Padova, Italy; ³Yale New Haven Transplant Center, Yale University, New Haven.
The model for end-stage disease (MELD) score is used to stratify candidates for liver transplant (LT) based on objective measures. Since June 2013 with changes…
2016 American Transplant Congress
The Effect of Body Mass Index on Lung Transplant Outcomes.
M. Kashem,¹ A. Shiose,¹ J. Abraham,¹ N. Dean,¹ S. Breves,¹ F. Cordova,² N. Patel,² T. Yoshizumi,¹ G. Criner,² Y. Toyoda.¹
¹Division of Cardiovascular Surgery, Temple University, Philadelphia, PA; ²Department of Thoracic Medicine and Surgery, Temple University, Philadelphia, PA.
Background: Lung transplant (LTx) has the potential to effectively extend the life expectancy for patients with end-stage lung disease. Both high and low body mass…